# Cold Atmospheric Pressure Plasma in Wound Healing and Cancer Treatment
## 3 CAP Application for Cancer Treatment
\begin{table}
\begin{tabular}{l l l l} \hline \hline \multicolumn{1}{c}{**Plasma Source**} & **Treatment of** & **Number of Participants** & **Reference (Year)** \\ \hline kINPen & Acute wounds & 6 & [15] (2014) \\ kINPen & Chronic wounds & 34 & [8] (2015) \\ kINJanPerm & Chronic wounds & 14 & [11] (2015) \\ kINPen & Chronic wounds & 16 & [9] (2015) \\ kINPen & Advanced squamous cell carcinoma of & 12 & [21] (2015) \\ BIOPlasma jet & Chronic wounds & 50 & [12] (2016) \\ kINPen & Advanced squamous cell carcinoma of & Group I: 12 & [22] (2016) \\ Custom-made device with hand-held & Group II: 9 & [22] (2017) \\ electrode (FPG10-01 NM10) & Actinic keratosis & 5 & [23] (2017) \\ kINPen & Locally advanced head and neck & 6 & [24] (2018) \\ Adtec Steri-Plas & Actinic keratosis & 7 & [25] (2018) \\ kINPen & Chronic wounds & 45 & [18] (2020) \\ plasma jet & Chronic wounds & 44 & [19] (2020) \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Cont. \begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline
**Reference** & **Device** & **Type** & **Feed Gas** & **Treatment Time** & **Repetition** & **Distance** & **slm** \\ \hline
[6] & MicroPlaSter \(\alpha\) & Torch & Argon & 5 min & daily (on average 7.86 treatments) & 20 mm & 2.2 \\ \hline
[20] & CPC 1500 System (jet) & Jet & Helium & 15–46 min & once & & \\ \hline
[7] & MicroPlaSter \(\alpha\)/\(\beta\) & Torch & Argon & 2 min & daily (on average 11.75 & & 2.2 \\ \hline
[13] & kINPen MED & Jet & Argon & 10 s, 30 s, or 3\(\times\)10 s & once & 10 mm & \\ \hline
[10] & MicroPlaSter \(\alpha\)/\(\beta\) & Torch & Argon & 3–7 min & daily (on average 7.90 treatments) & 20 mm & 2.2 \\ \hline
[16] & MicroPlaSter \(\beta\) & Torch & Argon & 2 min & daily except for weekend & 20 mm & 2.2 \\ \hline
[15] & kINPen MED & Jet & Argon & 1 min (8 mm/s) & once & 10 mm & 5.0 \\ \hline
[8] & kINPen 09 & Jet & Argon & 1 min/cm & once & 7–8 mm & 5.0 \\ \hline
[11] & PlasmaDerm & DBD & n/a (air) & 45 s/cm\({}^{2}\) & 3 x week for 8 weeks & n/a \\ \hline
[9] & kINPen MED & Jet & Argon & 1 min/cm & 3 x week for 2 weeks & 7–8 mm & 5.0 \\ \hline
[21] & kINPen MED & Jet & Argon & 1 min/cm\({}^{2}\) & 3 x week for 1 week & 8 mm & between 3–6 \\ \hline
[12] & BOPlasma jet & Jet & Argon & 1 min/cm\({}^{2}\) & 1 x week for 8 weeks & 1–3 mm & \\ \hline
[22] & kINPen MED & Jet & Argon & \begin{tabular}{c} Group 1: I min spot \\ exposure Group II: \\ 3 min spot exposure \\ \end{tabular} & \
\begin{tabular}{c} Group I: 3 x week for 1 weeks \\ Group II: once \\ \end{tabular} & 8 mm & \\ \hline \multirow{3}{*}{[23]} & Custom-made device with & & & & \\  & hand-held electrode & FE-DBD & n/a (air) & 1–2 min & once & 2.7 mm & n/a \\ \cline{1-1} \cline{2-6}  & (PFG10-01 NM10) & & & & &
\begin{tabular}{c} 3 x week for 1 week followed by \\ an intermittent 0 level \\ without CAP \\ \end{tabular} & 8 mm & 5.0 \\ \hline
[25] & Adtec Steri-Plas & Jet & & 2 min & 2 x week (7 treatments) & \\ \hline
[18] & kINPen MED & Jet & Argon & 30 s/cm\({}^{2}\) &
\begin{tabular}{c} 5 x daily, then 3 x every \\ second day \\ \end{tabular} & \\ \hline
[19] & plasma jet & Jet & Helium & 5 min & 3 x week for 3 weeks & 10 mm & \\ \hline \hline \end{tabular}
\end{table} 
Table 2: Frequently reported treatment parameters in clinical pilot studies and case reports of CAP application for treatment of chronic and acute wounds, as well as (pre-) cancerous tissues. In comparison to CAP use for wound healing, the clinical studies for CAP in oncology are still very sparse. Nonetheless, in vitro and in vivo studies, as well as the first clinical trials, are encouraging and warrant further efforts to prove the safety and efficacy of CAP as an innovative cancer therapy. Since there are many different devices and parameters that may influence treatment efficacy for wound healing, as well as for cancer therapy, a direct comparison of these studies is difficult. Nonetheless, comparing the different parameters may help to decipher which settings may be most promising. An overview of the most frequently reported parameters is provided in Table 2.